Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Ry%EF%BF%BD%EF%BF%BDka Ales) .

1 - 10 / 138
First pagePrevious page12345678910Next pageLast page
1.
2.
Spremembe gozdne vegetacije po požaru in digitalna sestojna kart
Boris Rantaša, Aleš Poljanec, 2024, preface, editorial, afterword

Keywords: digtalna sestojna karta, gozda vegetacija
Published in DiRROS: 20.05.2024; Views: 88; Downloads: 55
.pdf Full text (39,46 KB)

3.
4.
5.
Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
Renata Režonja, Iztok Grabnar, Tomaž Vovk, Aleš Mrhar, Viljem Kovač, Tanja Čufer, 2015, original scientific article

Abstract: Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrileneutropenia. Primary prophylaxis with granulocyte colonystimulating factors (G-CSFs) is not routinely recommended by the treatment guidelines. However, in clinical practice febrile neutropenia is often observed with standard etoposide/platinum regimen. The aim of this analysis was to evaluate the frequency of neutropenia and febrile neutropenia in advanced SCLC patients in the first cycle of standard chemotherapy. Furthermore, we explored the association between severe neutropenia and etoposide peak plasma levels inthe same patients. The case series based analysis of 17 patients with advanced SCLC treated with standard platinum/etoposide chemotherapy, already included in the pharmacokinetics study with etoposide, was performed. Grade 3/4 neutropenia and febrile neutropenia, observed after the first cycle are reported. The neutrophil counts were determined on day one of the second cycle unless symptoms potentially related to neutropenia occurred. Adverse events were classified according to Common Toxicity Criteria 4.0. Additionally, association between severe neutropenia and etoposide peak plasma concentrations, which were measured in the scope of pharmacokinetic study, was explored. Two out of 17 patients received primary GCS-F prophylaxis. In 15 patient who did not receive primary prophylaxis the rates of both grade 3/4 neutropenia and febrile neutropenia were high (8/15 (53.3%) and 2/15 (13.3%), respectively), already in the first cycle of chemotherapy. One patient died due to febrile neutropenia related pneumonia. Neutropenic events are assumed to be related to increased etoposide plasma concentrations after a standard etoposide and cisplatin dose. While the mean etoposide peak plasma concentration in the first cycle of chemotherapy was 17.6 mg/l, the highest levels of 27.07 and 27.49 mg/l were determined in two patients with febrile neutropenia. Our study indicates that there is a need to reduce the risk of neutropenic events in chemotherapy treated advanced SCLC, starting in the first cycle. Mandatory use of primary G-CSF prophylaxis might be considered. Alternatively, use of improved risk models for identification of patients with increased risk for neutropenia and individualization of primary prophylaxis based on not only clinical characteristics but also on etoposide plasma concentration measurement, could be a new, promising options that deserves further evaluation.
Keywords: small cell lung cancer, platinum-etoposide chemotherapy, etoposide, febrile neutropenia, plasma drug concentration
Published in DiRROS: 22.04.2024; Views: 128; Downloads: 60
.pdf Full text (568,43 KB)
This document has many files! More...

6.
7.
Konjugat protitelo-zdravilo za zdravljenje limfomov
Aleš Christian Mihelač, 2024, published professional conference contribution

Keywords: internistična onkologija, limfomi, kemoterapija
Published in DiRROS: 19.04.2024; Views: 124; Downloads: 32
.pdf Full text (771,38 KB)

8.
Higher levels of total pepsin and bile acids in the saliva as a possible risk factor for early laryngeal cancer
Maja Šereg Bahar, Aleš Jerin, Irena Hočevar-Boltežar, 2015, original scientific article

Abstract: Background. Gastroesophageal reflux is suspected to be an etiological factor in laryngeal and pharyngeal cancer. The aim of this study was to establish, using a non-invasive method, whether laryngopharyngeal reflux (LPR) appears more often in patients with early laryngeal cancer than in a control group. Patients and methods. We compared the pH, the level of bile acids, the total pepsin and the pepsin enzymatic activity in saliva in a group of 30 patients with T1 laryngeal carcinoma and a group of 34 healthy volunteers. Results. The groups differed significantly in terms of levels of total pepsin and bile acids in the saliva sample. Higher levels of total pepsin and bile acids were detected in the group of cancer patients. No significant impact of other known factors influencing laryngeal mucosa (e.g. smoking, alcohol consumption, and the presence of irritating substances in the workplace) on the results of saliva analysis was found. Conclusions. A higher level of typical components of LPR in the saliva of patients with early laryngeal cancer than in the controls suggests the possibility that LPR, especially biliary reflux, has a role in the development of laryngeal carcinoma.
Keywords: laryngopharyngeal reflux, gastric acid, pepsin, bile acids, laryngeal carcinoma
Published in DiRROS: 17.04.2024; Views: 186; Downloads: 104
.pdf Full text (558,42 KB)

9.
10.
Semirigid thoracoscopy : an effective method for diagnosing pleural malignancies
Aleš Rozman, Luka Camlek, Izidor Kern, Mateja Marc-Malovrh, 2014, original scientific article

Keywords: torakoskopija, plevra, diagnostika
Published in DiRROS: 04.04.2024; Views: 176; Downloads: 33
.pdf Full text (277,83 KB)

Search done in 0.38 sec.
Back to top